Only two peptides for weight loss carry serious trial evidence: semaglutide and tirzepatide. Both are approved for chronic weight management and both have placebo-controlled trials with tens of thousands of participants behind them. Almost everything else in the peptide conversation, from BPC-157 to CJC-1295 to AOD-9604, is marketed far beyond its data. Some are investigational, some are sold as research chemicals, and a few are simply hype. The gap between the two groups is not subtle.
What makes a peptide worth taking seriously?
The bar is boring but honest: randomized controlled trials, published results, and a regulatory review that checked the manufacturing and the safety signals. Semaglutide and tirzepatide clear that bar. In the SURMOUNT-1 trial, adults with obesity taking tirzepatide lost a large share of body weight over 72 weeks compared with placebo, with the higher doses reaching roughly a fifth of starting weight on average. That result was published in the New England Journal of Medicine in 2022 and confirmed in other populations, including the SURMOUNT-CN trial in Chinese adults reported in 2024.
Contrast that with the peptides trending on social media. Many have never been tested in a controlled human weight-loss trial at all. Being a peptide is not a mechanism. Insulin is a peptide. So is the poison in a cone snail. The category tells you almost nothing about whether a molecule helps a person lose weight safely.
Semaglutide or tirzepatide: is one better?
A direct comparison published in 2024 looked at adults with overweight or obesity and found tirzepatide produced greater weight reduction than semaglutide. That is a real finding, and it matters. But “greater average weight loss in a trial” is not the same as “the right choice for you.” Tolerability varies. Nausea, cost, injection frequency, and insurance all shape the decision. Some people do well on semaglutide and never need to switch.
There is also good evidence that these drugs do more than move the scale. A 2024 trial found tirzepatide improved obstructive sleep apnea in people with obesity, and current obesity guidelines increasingly frame these medications around the health conditions that travel with excess weight rather than weight alone. The 2025 clinical practice guideline update on pharmacotherapy for obesity treats them as first-line pharmacologic options for the right patients.
How do the main options compare?
| Peptide | Evidence status | Honest read |
|---|---|---|
| Semaglutide | Approved, large trials | Strong track record, well studied |
| Tirzepatide | Approved, large trials | Greater average loss in head-to-head data |
| Retatrutide | Investigational | Early data look promising, not yet approved |
| Compounded GLP-1 | Not FDA-approved | Predictable cash price, no approval behind it |
| BPC-157, CJC-1295, AOD-9604 | No controlled weight-loss trials | Mostly hype for this purpose |
Why do results vanish when people stop?
This is the part the marketing skips. These medications manage a chronic condition; they do not cure it. The SURMOUNT-4 trial, published in 2023, put people on tirzepatide, then either continued the drug or switched them to placebo. The continued group held onto their weight loss. The placebo group regained a substantial part of it. The lesson is not that the drug failed. It is that obesity behaves like other chronic conditions, and stopping the treatment tends to reverse the effect. Anyone comparing options should plan for the long term, not a single cycle.
What about the peptides going viral?
BPC-157 is promoted for healing and recovery. CJC-1295 and ipamorelin are sold as growth hormone secretagogues. AOD-9604 was once studied as a weight-loss agent and did not deliver in later trials. None of these has controlled human evidence supporting meaningful fat loss, and many are sold with “research use only” labeling that is a legal signal, not a health endorsement. Buying an unregulated vial off a website means no assurance of what is actually inside it. For weight loss specifically, spending money here is hard to defend.
Where do compounded versions fit, and what do they cost?
Compounded semaglutide and tirzepatide sit in a separate category from both the brands and the hype peptides. They are prepared by compounding pharmacies and are not FDA-approved products, which means they have not been through the review that produced the trial evidence for the brands. What they often provide is a flat monthly cash price without insurance involved, which appeals to people whose plans exclude weight-management drugs. Supervised telehealth practices such as FormBlends publish this kind of pricing, and a reader weighing the options can compare the tradeoffs in this in-depth guide before deciding. The framing that matters is simple: this route trades regulatory assurance for cost predictability, and that choice belongs with a prescriber who knows the case.
Several well-known telehealth names operate in this space too, including Ro, Hims and Hers, Henry Meds, LillyDirect, and NovoCare. Some connect patients to brand medication, some to compounded product, and the distinction is worth confirming before enrolling. The word “peptide” on a marketing page does not tell you which one you are getting.
How should someone actually decide?
Start with the diagnosis, not the drug. Recent work on the definition and diagnostic criteria of clinical obesity, along with the AGA guideline on pharmacological interventions for adults with obesity, pushes toward treating obesity as a medical condition with defined criteria rather than a cosmetic target. That matters because related conditions change the calculation. The EASL, EASD, and EASO guidelines on metabolic dysfunction-associated steatotic liver disease, for example, describe how weight-active therapy intersects with liver health. A person with sleep apnea, fatty liver, or type 2 diabetes has different reasons to consider these drugs than someone chasing a number.
The blunt summary: the two approved GLP-1 based options are the ones worth the conversation. Retatrutide is worth watching but is not approved. The viral recovery and growth-hormone peptides are not weight-loss drugs, whatever the ads imply.
Key takeaways
- Semaglutide and tirzepatide are the only weight-loss peptides with strong approved-drug evidence.
- In a direct comparison, tirzepatide produced greater average weight loss than semaglutide.
- Weight tends to return after stopping, so these are long-term therapies, not short cycles.
- Compounded versions are not FDA-approved, and viral peptides like BPC-157 lack weight-loss data.
See also: How a Compensation Lawyer Helps During a Claim Delay
Frequently asked questions
Which peptides for weight loss actually have strong evidence?
Semaglutide and tirzepatide have the strongest published trial evidence. Both are approved for chronic weight management and have head-to-head and placebo-controlled data behind them. Most other peptides marketed for fat loss have little or no controlled human weight-loss data.
Is tirzepatide better than semaglutide for weight loss?
In a direct comparison of adults with overweight or obesity, tirzepatide produced greater weight reduction than semaglutide. That does not make it right for everyone, since tolerability, cost, and access differ from person to person.
Are peptides like BPC-157 or CJC-1295 proven for weight loss?
No. These are heavily marketed but lack controlled human trials showing meaningful weight loss. Many are sold as research chemicals and are not FDA-approved products for any use.
Is compounded semaglutide the same as the brand?
No. Compounded versions are prepared by a compounding pharmacy and are not FDA-approved products. They may contain the same molecule but have not gone through the approval process behind the published brand trials.
Do the results last after stopping the medication?
Weight tends to return after stopping. A maintenance trial showed that continued treatment preserved weight reduction while switching to placebo led to regain, which is why these are framed as long-term therapies.
